Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.

AIDS research and human retroviruses - 1 Feb 2013

Rivero-Juarez Antonio, Mira Jose A, Santos-Gil Ignacio, Lopez-Cortes Luis F, Girón-Gonzalez Jose A, Marquez Manuel, Merino Dolores, Tellez Francisco, Caruz Antonio, Pineda Juan A, Rivero Antonio

Abstract excerpt

We assessed the relationship between atazanavir (ATV)-based antiretroviral treatment (ART) and plasma hepatitis C virus (HCV) viral load in a population of HIV/HCV-coinfected patients. HIV/HCV-coinfected patients who received ART based on a protease inhibitor (PI) or nonnucleoside reverse transcr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Antiretroviral Therapy, Highly Active

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coinfection

Share to Hepatitis C, Chronic

Share to Interferons

Share to Interleukins

Share to Oligopeptides

Share to Pyridines

Source

Open in PubMed Open full text

Identifiers

PMID: 22966845
DOI: 10.1089/AID.2012.0126
PMCID: PMC3552167

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22966845-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.PMID 22966845Read ↗

Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.Semantic proximity Read ↗

High serum HCV RNA in chronic hepatitis C patients coinfected with HIV despite successful antiretroviral therapy.Semantic proximity Read ↗

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).Semantic proximity Read ↗

Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.Semantic proximity Read ↗

Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.Semantic proximity Read ↗

Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.Semantic proximity Read ↗

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.Semantic proximity Read ↗

Changes in hepatitis C viral response after initiation of highly active antiretroviral therapy and control of HIV viremia in chronically co-infected individuals.Semantic proximity Read ↗

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.Semantic proximity Read ↗

Impact of highly active antiretroviral therapy and immunologic status on hepatitis C virus quasispecies diversity in human immunodeficiency virus/hepatitis C virus-coinfected patients.Semantic proximity Read ↗

The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients.Semantic proximity Read ↗

Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.